Dynavax to Present at Upcoming Investor Conferences
BERKELEY, CA--(Marketwired - September 05, 2017) - Dynavax Technologies Corporation (DVAX) announced today that the company will present at two upcoming investor conferences in September.
NewsMakers in the Biotech Industry Investor Conference
Friday, September 8, 2017 in New York at 8:30 a.m. Eastern Time
Cantor Fitzgerald Global Healthcare Conference
Wednesday, September 27, 2017 in New York at 4:00 p.m. Eastern Time
The live or replayed version of the webcast of each presentation will be available by visiting the company's corporate website at http://investors.dynavax.com/events.cfm.
About Dynavax
Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates that stimulate the immune response for use in multiple cancer indications and as a vaccine for the prevention of hepatitis B. Dynavax's lead product candidates are SD-101, an investigational cancer immunotherapeutic currently in Phase 2 studies, and HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)], a Phase 3 investigational adult hepatitis B vaccine currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Action date of November 9, 2017. For more information, visit www.dynavax.com.
